Article Text

Download PDFPDF

Viral hepatitis
P81 Psychiatric side effects of antiviral therapy with pegylated interferon and ribavirin are associated with poor response in children with chronic hepatitis C
  1. I Carey,
  2. C Pariante,
  3. S Bansal,
  4. P Subramaniam,
  5. S Tizzard,
  6. D Vergani,
  7. G Mieli-Vergani
  1. Institute of Liver Studies and Transplantation, King's College Hospital, London, UK


Introduction Chronic hepatitis C (CHC), a mild disease in childhood, can progress to cirrhosis in young adulthood. Successful Peg-IFN+ribavirin therapy prevents progression, but has, among others, neuropsychiatric (NP) side effects (SE) that might impact on response.

Aim To study the influence of Peg-IFN+ribavirin-related NPSE on treatment response in paediatric CHC using novel age-adapted questionnaires.

Method Patients: 21 CHC children (11 boys, median age 12 yrs) treated with Peg-IFN2a+Ribavirin were divided in responders (R) (n=13), relapsers (Rel) (n=4) and non-responders (NR) (n=4). Methods: NPSE (fatigue/low mood/irritability/depression/insomnia) were assessed at each clinic visit, irrespective of age. In 15 children aged =11 yrs, NP symptom severity was evaluated at baseline, treatment week 12 (TW12), TW24, TW48 and 6 mths post therapy, using in-house questionnaires measuring degree of fatigue and social adjustment. Fatigue questionnaire: 13 questions (scored −50 to 100/question) assessing fatigue/motivation/concentration/memory/basic cognitive function (speech/word recollection). Social adjustment questionnaire: five questions (scored 0–8/question) measuring impact of therapy on school attendance/homework/social leisure activities/private leisure activities/ability to make friends.

Results 11 patients (52%) developed NPSEs, low mood and irritability being higher in NR and Rel than R (75% and 75% vs 38%, p=0.03). Children >12 yrs developed NPSEs more often than those younger (8/11 (73%) vs 3/10 (30%), p=0.04). In 15 patients aged =11 yrs (median 13 yrs) there was no difference in severity of fatigue and social adjustment scales at baseline between R (n=9), NR (n=3) and Rel (n=3) (fatigue median score: 250, 250 and 275; median social adjustment scale: 5, 10 and 9). During therapy, fatigue severity increased similarly in all groups at TW12 (R: 625; Rel: 575; NR: 800), and tended to be higher in NR than Rel and R at TW24 and 48 (TW24: 1150 vs 700 and 725, p=0.06; TW48: 1000 vs 775 and 825, p=0.1). Six months after treatment, severity of fatigue returned to pre-treatment levels, but tended to remain higher in NR and Rel than in R (NR 400 vs Rel 325 vs R 250, p=0.09). Social adjustment scale increased in all patients during therapy, tending to be higher in Rel and NR than R at TW12 (R 15 vs Rel 20 vs NR 25, p=0.06), being higher in NR than in R and Rel at TW24 and 48 (TW24: R 20 vs Rel 30 vs NR 35, p=0.05; TW48: R 17.5 vs Rel 30 vs NR 35, p=0.04), remaining higher in NR and Rel than in R (NR 15 vs Rel 15 vs R 5, p=0.02) 6 months post therapy.

Conclusion Antiviral therapy-related NPSEs are associated with poor response in children with CHC.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.